see the new 8k posted on the Nasdaq site. These people have no shame and no clue about their responsibility to the shareholders. CEO, IR, Bus Dev, most of the BOD are dead wood and need to be replaced. IMO of course.
They need to do something to unlock the value and provide a return to the shareholders. I am sure they are all feeling the heat given the terrible relative performance YTD. If I were the responsible person at Vanguard, I would be on the phone weekly to find out WTH they are doing to turn things around.
should be up no? Maybe we will get some news from Roche, another partner, or the IV board soon.
What has happened in 3 months to drop the stock price by 33%? Industry is up, scripts are up, some new competitors, but not unexpected, Bel-Phen looks more likely, getting closer to smoking results. Jack is unfortunately still the CEO, that's the only negative I see.
Ignore the short hedge fund lies and buy/hold IMO. ARNA should be worth $6-8 within the next 12 months. I am going to hold and watch now, no time to read short lies or SV pumping.
if/when they do, ACAD will/would have a much higher market cap. It's not yet/far from a done deal. I am a bit skeptical about the thought that a tiny biotech will successfully supply 100,000+ patients. Seems like a tall task and the reason a large pharma should buy them at a reasonable price.
I think it's time to load up, just IMO. I get the feeling something is happening. Why have they not hired an IR person? I could have found then 3-4 good people in 1-2 months. It might be that no self respecting IR person wants to work for Jack, or...the company is considering options for which they would not need an IR pro. Bottom line, stock is cheap, problems are fixable, 1) get rid of Jack 2) get rid of Jack 3) insiders/directors buy some stock 4) find some new institutional buyers 5) do some deals 6) do some deals that lower the burn rate or 7) just sell to the highest bidder.
IMGN's big news is they hired another new SVP. Sutro, SGEN actually have deals, drug news, clinical developments. Almost another year has passed with NO NEW significant drug development or deal news from IMGN. WTH are they doing there???
Let's say 100,000 patients is accurate and the annual cost is $10,000 (wild guess) that would be $1BB. ARNA's drug, has some similarities, retails for about $250 (before discounts), I think that's for a 1 month supply. So, pricing could be $3000/yr or higher.
incompetence, supporting the short sellers, working against the shareholders. While Jack is doing nothing, anyone know what Cindy is doing in Switzerland? It's very expensive to live there, we need some results, some return on investing in her high expenses. Soon we will have the increased expenses of a new IR person while paying for an absent, former IR person. At least execs and the absent BOD could buy some stock at $3.90 for goodness sake.
That's TERRIBLE performance. Institutional ownership% is way too low, stock performance is unacceptable! ARNA execs need to get their act together and start focusing on the shareholders, or get OUT!
In your revs and earnings model are you assuming 2 Bel and Phen 2 or 1B and 2P like the small trial? Since the weight loss effects of the Phen eventually diminish, I could see continued Bel as LT maintenance after weight loss goals are met. Eventually (if/when) the LAR version should replace the 10Mg tablets.
You can read more by visiting the IV board. Excellent results for TDM1 in patients with Her+ cancer that has spread to the brain. Another potential revenue generator the is not getting any attention, or IR.
This prospective case series again indicates relevant clinical activity of systemic treatment in Her2-positive BM. LapCap remains the standard of care but results of this analysis warrants further investigation of T-DM1 in BM in the context of prospective clinical studies."